InvestorsHub Logo
icon url

slickinvest

06/24/20 12:19 PM

#48506 RE: EOT #48505

She’s getting really thin $$SBFM
icon url

StockRoomBully

06/24/20 12:26 PM

#48509 RE: EOT #48505

MCGILL University news closer than ever

Good news in queue

https://www.mcgill.ca/search/Cancer

This mechanism acts efficiently in other types of cancer resistant to current therapies.





A month after being injected with PJ34 daily for 14 days, the pancreatic cancer cells in the tumors of the treated mice experienced a relative drop of 90%. In one mouse, the tumor completely disappeared.

"It is important to note that no adverse effects were observed, and there were no changes in the weight gain of the mice, nor in their behavior," says Prof. Cohen-Armon.

This mechanism acts efficiently in other types of cancer resistant to current therapies. The molecule PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials begin.




New in queue. Over due

MONTREAL, QC / ACCESSWIRE / October 17, 2019 / Sunshine Biopharma, Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has initiated studies of Adva-27a in xenograft mice. In these studies, specifically engineered mice which have developed tumors following injection with patient derived cancer cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors. Among the different types of patient derived cancer types being studied are Pancreatic Cancer, Breast Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.





https://www.sciencedaily.com/releases/2019/12/191203102018.htm